Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Randomized Open-label Comparative Study of the Use of Intranasal Form of Interferon Gamma Human Recombinant in Patients for the Prevention of Acute Respiratory Viral Infections, Including COVID-19

NCT05054114 is registered in ClinicalTrials.gov with SPP Pharmaclon Ltd. as lead sponsor.

NCT NCT05054114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05054114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Randomized Open-label Comparative Study of the Use of Intranasal Form of Interferon Gamma Human Recombinant in Patients for the Prevention of Acute Respiratory Viral Infections, Including COVID-19
Lead sponsor
SPP Pharmaclon Ltd.
Phase
Not applicable
Overall status
Completed
Start date
December 21, 2020
Completion date
September 2, 2021
Enrollment
630 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory disease, covid-19 respiratory infection